See more : Aker Carbon Capture ASA (ACC.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Petros Pharmaceuticals, Inc. (PTPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Petros Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hudson Executive Investment Corp. III (HIII) Income Statement Analysis – Financial Results
- Rent the Runway, Inc. (RENT) Income Statement Analysis – Financial Results
- Coast Copper Corp. (COCO.V) Income Statement Analysis – Financial Results
- Nogin, Inc. (NOGN) Income Statement Analysis – Financial Results
- aTyr Pharma, Inc. (ATYR) Income Statement Analysis – Financial Results
Petros Pharmaceuticals, Inc. (PTPI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.petrospharma.com
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.82M | 5.99M | 7.81M | 9.56M | 15.58M | 14.05M |
| Cost of Revenue | 1.63M | 2.29M | 1.60M | 4.05M | 7.43M | 10.48M |
| Gross Profit | 4.19M | 3.70M | 6.21M | 5.51M | 8.15M | 3.57M |
| Gross Profit Ratio | 71.98% | 61.79% | 79.52% | 57.67% | 52.32% | 25.41% |
| Research & Development | 2.41M | 1.74M | 1.79M | 459.64K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -41.15K |
| SG&A | 9.26M | 12.21M | 15.59M | 15.67M | 19.73M | 11.22M |
| Other Expenses | 6.14M | 5.60M | 6.88M | 6.66M | 5.29M | 0.00 |
| Operating Expenses | 17.81M | 19.55M | 24.26M | 22.80M | 25.02M | 11.22M |
| Cost & Expenses | 19.44M | 21.84M | 25.86M | 26.84M | 32.45M | 21.70M |
| Interest Income | 515.31K | 14.19K | 368.66K | 3.05M | 13.84M | 11.86M |
| Interest Expense | 536.14K | 596.02K | 368.66K | 3.05M | 13.84M | 0.00 |
| Depreciation & Amortization | 3.42M | 5.72M | 6.98M | 6.75M | 5.32M | 8.06M |
| EBITDA | -4.21M | -13.73M | -1.64M | -12.21M | -14.00M | 373.58K |
| EBITDA Ratio | -72.34% | -114.20% | -143.00% | -111.11% | -74.32% | 2.95% |
| Operating Income | -13.62M | -15.85M | -18.05M | -17.28M | -16.87M | -7.65M |
| Operating Income Ratio | -233.88% | -264.45% | -231.05% | -180.78% | -108.29% | -54.45% |
| Total Other Income/Expenses | 5.45M | -121.82K | 9.06M | -4.73M | -13.84M | -24.84M |
| Income Before Tax | -8.16M | -20.04M | -8.99M | -22.01M | -33.16M | -32.49M |
| Income Before Tax Ratio | -140.20% | -334.40% | -115.05% | -230.27% | -212.86% | -231.20% |
| Income Tax Expense | 0.00 | 7.00M | 368.66K | -1.43M | -645.87K | -13.37K |
| Net Income | -8.16M | -27.04M | -9.36M | -20.59M | -32.51M | -32.47M |
| Net Income Ratio | -140.20% | -451.22% | -119.77% | -215.35% | -208.71% | -231.10% |
| EPS | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| EPS Diluted | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| Weighted Avg Shares Out | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
| Weighted Avg Shares Out (Dil) | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer...
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer,...
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY /...
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a...
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design...
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused...
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
(Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs,...
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of...
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status (Please see important safety information below) NEW YORK, NY / ACCESSWIRE /...
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding...
Source: https://incomestatements.info
Category: Stock Reports